Avior Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Avior Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$10.9K	–	1705
2023 Q1	$10.9K	Sell	100 -2,571	-96%	-$284K	﹤0.01%	1038
2022 Q4	$304K	Hold	2,671	–	–	0.02%	401
2022 Q3	$165K	Hold	2,671	–	–	0.01%	474
2022 Q2	$212K	Hold	2,671	–	–	0.02%	414
2022 Q1	$280K	Buy	2,671 +2,571	+2,571%	+$251K	0.02%	394
2021 Q4	$10K	Hold	100	–	–	﹤0.01%	813
2021 Q3	$10K	Sell	100 -3,439	-97%	-$357K	﹤0.01%	770
2021 Q2	$331K	Sell	3,539 -5,087	-59%	-$468K	0.03%	354
2021 Q1	$793K	Sell	8,626 -2,004	-19%	-$169K	0.08%	210
2020 Q4	$777K	Buy	+10,630	New	+$790K	0.1%	186

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Avior Wealth Management's HZNP Position: Q2 2023 in Review

Avior Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 100 shares — an estimated $10.9K sold.

Avior Wealth Management first reported a position in HZNP in Q4 2020 and held it in 10 quarters. The position peaked at $793K in Q1 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Avior Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Avior Wealth Management sold 100 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $10.9K.
Avior Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 10 quarters.
Avior Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $793K in Q1 2021.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Avior Wealth Management's 13F filing for Q2 2023, filed 19 Jul 2023.